Patients with ejection fraction <40% were excluded. Patients were randomized to receive perindopril 2 mg daily or placebo. The primary outcome, the composite of all-cause mortality or unplanned ...

[33] Perindopril 8 mg/day reduced the primary combined endpoint of death, hospitalisation for heart failure, or left ventricular remodelling by 22% (p < 0.001) in a randomised trial evaluating ...

Angiotensin II type 1 and 2 receptors (AT 1 and AT 2 ... Over a period of 24 weeks, 10 patients with MFS received 8 mg perindopril daily, and 7 patients received placebo. Patients on perindopril ...